Molecular biology of liver carcinogenesis and hepatitis

Blumgart's Surgery of the Liver, Biliary Tract and Pancreas

Volumn , Issue , 2012, Pages 142-152

  Shimoda, Masafumi ^a   Wands, Jack R ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884749938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1454-8.00109-0     Document Type: Chapter

References (127)

1. A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999, 29:946-953.
2. Bataller R, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126:529-540.
3. Bataller R, Brenner DA Liver fibrosis. J Clin Invest 2005, 115:209-218.
4. Bertoletti A, Ferrari C Kinetics of the immune response during HBV and HCV infection. Hepatology 2003, 38:4-13.
5. Boige V, et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997, 57:1986-1990.
6. Boissan M, et al. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 2005, 167:869-877.
7. Bouchard MJ, et al. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294:2376-2378.
8. Bouchard MJ, Schneider RJ The Enigmatic X gene of hepatitis B virus. J Virol 2004, 78:12725-12734.
9. Branda M, Wands JR Signal transduction cascades and hepatitis B and C-related hepatocellular carcinoma. Hepatology 2006, 43:891-902.
10. Bréchot C Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000, 10:211-231.
11. Bressac B, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
12. Breuhahn K, et al. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25:3787-3800.
13. Calvisi DF, et al. Activation of ?-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001, 61:2085-2091.
14. Calvisi DF, et al. Disruption of ?-catenin pathway or genomic instability defines two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004, 126:1374-1386.
15. Cantarini MC, et al. Aspartyl-asparagyl ? hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. Hepatology 2006, 44:446-457.
16. Chami M, et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000, 19:2877-2886.
17. Chang MH, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
18. Chen HS, et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993, 67:1218-1226.
19. Chisari F, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
20. Chiu CM, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A 2007, 104:2571-2578.
21. Davila JA, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
22. de la Coste A, et al. Somatic mutations of the ?-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998, 95:8847-8851.
23. Donato F, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323-331.
24. Elmore LW, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997, 94:14707-14712.
25. El-Serag HB, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
26. El-Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
27. Farazi PA, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003, 63:5021-5027.
28. Farazi PA, DePinho RA Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
29. Fattovich G Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47-58.
30. Fattovich G, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
31. Feitelson MA, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002, 21:2593-2604.
32. Ferber MJ, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003, 22:3813-3820.
33. Foy E, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
34. Fujito T, et al. Prognostic significance of ?-catenin nuclear expression in hepatocellular carcinoma. Hepatogastroenterology 2004, 51:921-924.
35. Fukutomi T, et al. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of Wnt-1 expression. Hepatology 2005, 41:1096-1105.
36. Furutani T, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130:2087-2098.
37. Garcia M, et al. Global Cancer Facts and Figures 2007 2007, American Cancer Society, Atlanta, Ga. http://www.cancer.org/acs/groups/content/anho/documents/document/globalfactsandfigures2007rev2p.pdf.
38. Giannelli G, et al. Laminin-5 with transforming growth factor-?1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383.
39. Gramantieri L, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007, 67:6092-6099.
40. Gressner OA Less Smad2 is good for you! A scientific update on coffee's liver benefits. Hepatology 2009, 50:970-978.
41. Hassan MM, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36:1206-1213.
42. Hertl M, Cosimi AB Liver transplantation for malignancy. Oncologist 2005, 10:269-281.
43. Higashitsuji H, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000, 6:96-99.
44. Higashitsuji H, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8:75-87.
45. Huang H, et al. ?-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999, 155:1795-1801.
46. Huo TI, et al. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 2001, 20:3620-3628.
47. Inagawa S, et al. Expression and prognostic roles of ?-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002, 8:450-456.
48. Inoue M, et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005, 97:293-300.
49. Inui Y, et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994, 107:1799-1804.
50. Ishido S, Hotta H Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett 1998, 438:258-262.
51. Ishizaki Y, et al. Immunohistochemical analysis and mutational analyses of ?-catenin, AXIN family and APC genes in hepatocellular carcinomas. Int J Oncol 2004, 24:1077-1083.
52. Ito Y, et al. Expression and clinical significance of Erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001, 84:1377-1383.
53. Ito Y, et al. Expression of heparin-binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001, 8:903-907.
54. Jhappan C, et al. TGF? overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990, 15:1137-1146.
55. Jia L, et al. Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 1999, 80:875-879.
56. Jin M, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000, 89:60-68.
57. Kanai Y, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999, 29:703-709.
58. Kao JH, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003, 124:327-334.
59. Kew MC Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003, 23:405-499.
60. Kim CM, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
61. Kota J, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
62. Kuang SY, et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 2004, 101:3575-3580.
63. Kwun HF, et al. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001, 82:2235-2241.
64. Laurent-Puig P, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
65. Laurent-Puig P, Zucman-Rossi J Genetics of hepatocellular tumors. Oncogene 2006, 25:3778-3786.
66. Lee CM, et al. Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. Hepatogastroenterology 2004, 51:796-800.
67. Lee HC, et al. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006, 131:1208-1217.
68. Lee S, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378.
69. Levrero M Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847.
70. INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999, 18:789-795.
71. Lin Y, et al. Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann Acad Med Singapore 1996, 25:22-30.
72. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
73. Longato L, et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009, 49:1935-1943.
74. Ma WL, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008, 135:947-955.
75. Machida K, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 2006, 80:7199-7207.
76. Mao TL, et al. Expression of mutant nuclear ?-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001, 193:95-101.
77. INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999, 116:394-400.
78. McGlynn KA, et al. International trends and patterns of primary liver cancer. Int J Cancer 2001, 94:290-296.
79. Meng F, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
80. Merle P, et al. Functional consequences of Frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004, 127:1110-1122.
81. Merle P, et al. Oncogenic role of the Frizzled-7/?-catenin pathway in hepatocellular carcinoma. J Hepatol 2005, 43:854-862.
82. Moriya K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-1067.
83. Murakami S Hepatitis B virus X protein: structure, function and biology. Intervirology 1999, 42:81-99.
84. Murakami Y, et al. Large-scaled analysis of hepatitis B virus (HBV) DNA integration in HBV-related hepatocellular carcinomas. Gut 2005, 54:1162-1168.
85. Murata H, et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab Invest 2004, 84:1050-1059.
86. Nagai H, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997, 14:2927-2933.
87. Naganuma A, et al. Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells. Cancer Res 2004, 64:1307-1314.
88. Nagao K, et al. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol 1999, 34:83-87.
89. Nishimoto A, et al. Functional evidence for a telomerase repressor gene on human chromosome 10p15.1. Oncogene 2001, 20:828-835.
90. Nishiyama M, Wands JR Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992, 183:280-285.
91. Ogata H, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006, 131:179-193.
92. Parkin DM, et al. Cancer Incidence in Five Continents 2002, vol VIII, no 155. IARC Scientific Publications, France, IARC Press, Lyon.
93. Paterlini-Bréchot P, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22:3911-3916.
94. Perz JF, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
95. Plentz RR, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004, 40:80-86.
96. Pollak M, et al. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
97. Polyak SJ, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001, 75:6095-6106.
98. Ray RB, et al. Hepatitis C virus core protein cooperates with Ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996, 70:4438-4443.
99. Rehermann B, Nascimbeni M Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
100. Reyes GR The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 2002, 9:187-197.
101. Russell WE, et al. Liver regeneration and hepatocarcinogenesis in transforming growth factor-?-targeted mice. Mol Carcinog 1996, 15:183-189.
102. Saeki A, et al. Frequent impairment of the spindle-assembly checkpoint in hepatocellular carcinoma. Cancer 2002, 94:2047-2054.
103. Satoh S, et al. AXIN1 mutations in hepatocellular carcinomas and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-250.
104. Schaff Z, et al. Overexpression of transforming growth factor-? in hepatocellular carcinoma and focal nodular hyperplasia from European patients. Hum Pathol 1994, 25:644-651.
105. Shimojima M, et al. Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol Res 2004, 29:31-38.
106. Smith MW, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003, 63:859-864.
107. Street A, et al. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004, 279:12232-12241.
108. Street A, et al. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular ?-catenin and stimulation of ?-catenin-responsive transcription. J Virol 2005, 79:5006-5016.
109. Takeo S, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 2001, 130:127-132.
110. Tanaka S, et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997, 26:598-604.
111. Tannapfel A, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001, 20:7104-7109.
112. Tellinghuisen TL, Rice CM Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 2002, 5:419-427.
113. Theise ND, et al. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002, 6:497-512.
114. Thompson MD, Monga SPS Wnt/?-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
115. Thorgeirsson SS, Grisham JW Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
116. Urabe Y, et al. Telomere length in human liver diseases. Liver 1996, 16:293-297.
117. Wands JR Prevention of hepatocellular carcinoma. N Engl J Med 2004, 351:1567-1570.
118. Wang XW, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994, 91:2230-2234.
119. Wang XW, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995, 55:6012-6016.
120. INK4A methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001, 84:982-989.
121. Wong CM, et al. ?-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001, 92:136-145.
122. Wong N, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999, 154:37-43.
123. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
124. Yeh YC, et al. Elevation of transforming growth factor ? and its relationship to the epidermal growth factor and ?-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987, 47:896-901.
125. Yu J, et al. Methylation profiling of twenty-four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003, 13:319-333.
126. Zhang J, et al. Expression of transforming growth factor-? and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol 2004, 15:830-833.
127. Zhang X, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994, 54:4177-4182.